52909-60-1

Usage

Uses

Used in Organic Synthesis:
1-Cyclopentene-1-carboxylic acid, 2-amino-, methyl ester (9CI) is used as a key intermediate in organic synthesis for the creation of various complex organic molecules. Its unique structure, which includes a cyclopentene ring, an amino group, and a methyl ester, allows it to participate in a range of chemical reactions, facilitating the synthesis of diverse organic compounds.
Used in Chemical Research:
In the field of chemical research, 1-Cyclopentene-1-carboxylic acid, 2-amino-, methyl ester (9CI) serves as a valuable compound for studying reaction mechanisms, exploring new synthetic pathways, and understanding the properties of related compounds. Its reactivity and structural features make it an interesting subject for scientific investigation.
Used in Pharmaceutical Industry:
1-Cyclopentene-1-carboxylic acid, 2-amino-, methyl ester (9CI) is used as a building block in the development of pharmaceuticals. Its potential applications in this industry may include the synthesis of novel drug candidates, the modification of existing drugs to improve their efficacy or reduce side effects, and the creation of prodrugs that are converted into active pharmaceutical ingredients within the body.
Used in Agrochemicals:
In the agrochemical sector, 1-Cyclopentene-1-carboxylic acid, 2-amino-, methyl ester (9CI) may be utilized in the synthesis of new pesticides, herbicides, or other agricultural chemicals. Its unique chemical properties could contribute to the development of more effective and environmentally friendly products for crop protection and management.

Upstream product

• 86993-49-9 C₇H₁₁BrNO₂^(1-)*Br^(1-)*Zn⁽²⁺⁾ 
• 86993-50-2 C₈H₁₄NO₅S^(1-)*Br^(1-)*Zn⁽²⁺⁾ 
• 10472-24-9 methyl 2-oxocyclopentane-1-carboxylate 
• 631-61-8 ammonium acetate 

Downstream Products

• 592503-43-0 2-acetylaminocyclopent-1-enecarboxylic acid methyl ester 
• 1042148-49-1 C₂₂H₂₃NO₃ 
• 5661-01-8 6,7-dihydro-3H-cyclopenta[d]pyrimidin-4(5H)-one 
• 83942-13-6 4-chloro-6,7-dihydro-5H-cyclopenta[d]pyrimidine 
• 1452392-79-8 N-(4-methoxyphenyl)-N-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-amine 
• 1452392-81-2 N-methyl-N-p-tolyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-amine 
• 1452392-82-3 N-(4-chlorophenyl)-N-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-amine 
• 1452392-83-4 N-methyl-N-(4-(methylthio)phenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-amine 
• 1452392-88-9 N-(4-methoxyphenyl)-N-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-aminium chloride 
• 1452392-89-0 N-(4-ethoxyphenyl)-N-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-aminium chloride 
• 5661-01-8 6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ol 
• 1621363-40-3 methyl 2-(4-((2-(5-bromothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)oxy)phenyl)acetate 
• 927837-20-5 cis-2-acetylaminocyclopentanecarboxylic acid methyl ester 

Relevant academic research and scientific papers

Silica Gel-mediated Synthesis of β-Enamino Esters and its Application for the Synthesis of Indeno 4-Hydroxypyridin-2(1H)-Ones

The full scope of SiO2-based condensation of aliphatic or aromatic amines and β-keto esters to give β-enamino esters was examined. Functionalized linear β-enamino esters were easily obtained from SiO2-based condensation of β-keto esters and amines only after simple filtration. It was also demonstrated that cyclic β-enamino esters with 99% purity can be prepared in a practically large scale (60 g) without using silica gel column chromatography. The utility of the present method was fortified by the preparation of pharmaceutically useful indeno-4-hydroxypyridin-2(1H)-one analogue 11.

BIARYL DERIVATIVE AS GPR120 AGONIST

The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS

The invention relates to novel substituted condensed pyrimidine compounds of general formula (I) in which the chemical groupings, substituents and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.

Synthesis of febrifugine derivatives and development of an effective and safe tetrahydroquinazoline-type antimalarial

Febrifugine, a quinazoline alkaloid isolated from Dichroa febrifuga roots, shows powerful antimalarial activity against Plasmodium falciparum. Although the use of ferifugine as an antimalarial drug has been precluded because of its severe side effects, its potent antimalarial activity has stimulated medicinal chemists to pursue its derivatives instead, which may provide valuable leads for novel antimalarial drugs. In the present study, we synthesized new derivatives of febrifugine and evaluated their in vitro and in vivo antimalarial activities to develop antimalarials that are more effective and safer. As a result, we proposed tetrahydroquinazoline-type derivative as a safe and effective antimalarial candidate.

Structure-activity relationship and in vitro and in vivo evaluation of the potent cytotoxic anti-microtubule agent N-(4-methoxyphenyl)-N,2,6-trimethyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-4-aminium chloride and its analogues as antitumor agents

A series of 21 substituted cyclopenta[d]pyrimidines were synthesized as an extension of our discovery of the parent compound (±)-1·HCl as an anti-microtubule agent. The structure-activity relationship indicates that the N-methyl and a 4N-methoxy groups appear important for potent activity. In addition, the 6-substituent in the parent analogue is not necessary for activity. The most potent compound 30·HCl was a one to two digit nanomolar inhibitor of most tumor cell proliferations and was up to 7-fold more potent than the parent compound (±)-1·HCl. In addition, 30·HCl inhibited cancer cell proliferation regardless of Pgp or βIII-tubulin status, both of which are known to cause clinical resistance to several anti-tubulin agents. In vivo efficacy of 30·HCl was demonstrated against a triple negative breast cancer xenograft mouse model. Compound 30·HCl is water-soluble and easily synthesized and serves as a lead compound for further preclinical evaluation as an antitumor agent.

Tetrahydro anthranilic acid as a surrogate for anthranilic acid: Application to the discovery of potent niacin receptor agonists

The design, synthesis, and biological activity of a series of cycloalkene acid-based niacin receptor agonists are described. This led to the discovery that tetrahydro anthranilic acid is an excellent surrogate for anthranilic acid. Several compounds were identified that were potent against the niacin receptor, had enhanced cytochrome P450 selectivity against subtypes CYP2C8 and CYP2C9, and improved oral exposure in mice.

Development of practical rhodium phosphine catalysts for the hydrogenation of β-dehydroamino acid derivatives

The rhodium-catalyzed asymmetric hydrogenation of various β-dehydroamino acid derivatives to give optically active β-amino acids has been examined. Chiral monodentate 4,5-dihydro-3H-dinaphthophosphepines, which are easily tuned and accessible in a multi-10-g scale, have been used as ligands. The enantioselectivity is largely dependent on the nature of the substituent at the phosphorous atom and on the structure of the substrate. Applying optimized conditions up to 94% ee was achieved.

Niacin receptor agonists, compositions containing such compounds and methods of treatment

The present invention encompasses compounds of Formula I: as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.

Method for producing an optically active beta-amino acid

To provide a producing method of an optically active β-amino acid useful as intermediate for the production of medicines, agricultural chemicals and physiologically active substances, by means of a catalytic and asymmetric synthesis method of high performance and a high enantiomeric excess, without requiring additional procedures such as introduction and removal of protecting group and so on. A producing method of an optically active β-amino acids which comprises subjecting an enamine to an asymmetric hydrogenation.

Enantioselective hydrogenation of tetrasubstituted olefins of cyclic β-(acylamino)acrylates

Hydrogenation of a series of cyclic β-(acylamino)acrylates with tetrasubstituted olefins has been accomplished successfully with the use of Ru catalysts with chiral biaryl ligands such as C3-TunaPhos, and up to over 99% ee's have been achieved. This methodology provides an efficient catalytic method for the synthesis of both cis and trans chiral cyclic β-amino acid derivatives. Copyright